Gergis Altalab
Gergis Altalab has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Izere Salomon
College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
2 shared publications - Khaled Moghib
Faculty of Medicine, Kasr Al-Ainy, Cairo University
2 shared publications - Ahmed Hafez Mousa
Neurosciences, Dubai Health, Dubai, United Arab Emirates
1 shared publication - Ahmed Harb
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication - Ahmed I. Elsekhary
Faculty of Medicine, Kasr Al-Ainy, Cairo University, Cairo, Egypt
1 shared publication - Ahmed Ibrahim Edress
Department of Neurosurgery, Tanta University, Tanta, Egypt
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Stereotactic radiosurgery for pituitary metastases: a systematic review and single-arm meta-analysis of local control and survival outcomes
Background Pituitary metastases (PM) are rare intracranial secondary tumors, most often arising from breast and lung primaries. They are clinically significant due to their association with advanced systemic malignancy and potential to cause visual, neurological, and endocrinological morbidity. Conventional therapies such as surgery and fractionated radiotherapy have limited efficacy or high morbidity. Stereotactic radiosurgery (SRS) has emerged as a minimally invasive alternative, but available evidence is limited to small, heterogeneous series. Objective To evaluate the effectiveness and safety of SRS in patients with PM by synthesizing data on tumor control, survival outcomes, progression-free survival (PFS), and treatment-related morbidity. Methods A systematic review and meta-analysis were performed according to PRISMA guidelines. PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched through June 2025. Eligible studies included patients with radiologically or histologically confirmed PM treated with SRS. Outcomes of interest were local tumor control, survival, PFS, radiological response, and complications, including hypopituitarism, optic neuropathy, and radiation necrosis. Data were pooled using a random-effects single-arm meta-analysis model. Results Six retrospective case series comprising 142 patients were included. Pooled local control following SRS was 89% (95% CI 75–96%). Six-month PFS was 97% (95% CI 83–100%). One- and two-year survival rates were 53% (95% CI 32–73%) and 40% (95% CI 15–72%), respectively. Tumor regression occurred in 34% and stable disease in 33%, while only 7% demonstrated progression. Treatment-related morbidity was low: new-onset hypopituitarism (1%), optic neuropathy (2%), and radiation necrosis (1%). Conclusion SRS provides effective and durable local control of pituitary metastases with a favorable safety profile and low rates of treatment-related toxicity. Despite the poor systemic prognosis associated with PM, SRS offers meaningful intracranial disease control and symptom relief, particularly in well-selected patients with stable systemic disease. Larger prospective, standardized studies are needed to further clarify long-term endocrine and neurological outcomes.
- 19 June 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessStereotactic radiosurgery for pituitary metastases: a systematic review and single-arm meta-analysis of local control and survival outcomes
Background Pituitary metastases (PM) are rare intracranial secondary tumors, most often arising from breast and lung primaries. They are clinically significant due to their association with advanced systemic malignancy and potential to cause visual, neurological, and endocrinological morbidity. Conventional therapies such as surgery and fractionated radiotherapy have limited efficacy or high morbidity. Stereotactic radiosurgery (SRS) has emerged as a minimally invasive alternative, but available evidence is limited to small, heterogeneous series. Objective To evaluate the effectiveness and safety of SRS in patients with PM by synthesizing data on tumor control, survival outcomes, progression-free survival (PFS), and treatment-related morbidity. Methods A systematic review and meta-analysis were performed according to PRISMA guidelines. PubMed, Embase, Scopus, Web of Science, and Cochrane Library were searched through June 2025. Eligible studies included patients with radiologically or histologically confirmed PM treated with SRS. Outcomes of interest were local tumor control, survival, PFS, radiological response, and complications, including hypopituitarism, optic neuropathy, and radiation necrosis. Data were pooled using a random-effects single-arm meta-analysis model. Results Six retrospective case series comprising 142 patients were included. Pooled local control following SRS was 89% (95% CI 75–96%). Six-month PFS was 97% (95% CI 83–100%). One- and two-year survival rates were 53% (95% CI 32–73%) and 40% (95% CI 15–72%), respectively. Tumor regression occurred in 34% and stable disease in 33%, while only 7% demonstrated progression. Treatment-related morbidity was low: new-onset hypopituitarism (1%), optic neuropathy (2%), and radiation necrosis (1%). Conclusion SRS provides effective and durable local control of pituitary metastases with a favorable safety profile and low rates of treatment-related toxicity. Despite the poor systemic prognosis associated with PM, SRS offers meaningful intracranial disease control and symptom relief, particularly in well-selected patients with stable systemic disease. Larger prospective, standardized studies are needed to further clarify long-term endocrine and neurological outcomes.
- Open Access
- 25 August 2025
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 8
Post-craniotomy headache and botulinum toxin A: A systematic review of case reports and case series
Background: Post-craniotomy headache (PCH) is a common, often debilitating complication with limited treatment options and unclear pathophysiology. While botulinum toxin A (BoNT-A) is effective for various headache disorders, its use in PCH is underexplored. This systematic review examines case reports and series on BoNT-A's efficacy and safety for PCH. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted in February 2025 using relevant keywords. Case reports and series on BoNT-A treatment for PCH were included, while unrelated studies, reviews, and incomplete abstracts were excluded. Data on patient characteristics, treatment protocols, efficacy, and adverse events were extracted. Results: Five case series published up to 2025 report on 15 patients from France, Canada, and the United States. Each study enrolled only three or four patients, all with persistent PCH unresponsive to standard analgesics. BoNT-A regimens differed widely, ranging from 15 to 165 U, and included single versus repeated sessions, as well as injection sites such as the temporalis muscle, incision margins, and cranial suture lines, highlighting the lack of a standardized protocol. Eleven patients achieved 75–100% pain relief within 10–15 days, with therapeutic effects persisting for several weeks to over 5 years. Many also demonstrated improvements in daily functioning and a reduction in analgesic consumption. No serious adverse events were reported, supporting BoNT-A as a safe and promising treatment for PCH. Conclusion: BoNT-A is a well-tolerated and effective option for patients with refractory PCH, offering substantial pain relief and functional improvement. However, given the reliance on small-scale studies, larger clinical trials are needed to confirm its efficacy and establish standardized treatment protocols.
- 25 August 2025
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 8
Open AccessPost-craniotomy headache and botulinum toxin A: A systematic review of case reports and case series
Background: Post-craniotomy headache (PCH) is a common, often debilitating complication with limited treatment options and unclear pathophysiology. While botulinum toxin A (BoNT-A) is effective for various headache disorders, its use in PCH is underexplored. This systematic review examines case reports and series on BoNT-A's efficacy and safety for PCH. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted in February 2025 using relevant keywords. Case reports and series on BoNT-A treatment for PCH were included, while unrelated studies, reviews, and incomplete abstracts were excluded. Data on patient characteristics, treatment protocols, efficacy, and adverse events were extracted. Results: Five case series published up to 2025 report on 15 patients from France, Canada, and the United States. Each study enrolled only three or four patients, all with persistent PCH unresponsive to standard analgesics. BoNT-A regimens differed widely, ranging from 15 to 165 U, and included single versus repeated sessions, as well as injection sites such as the temporalis muscle, incision margins, and cranial suture lines, highlighting the lack of a standardized protocol. Eleven patients achieved 75–100% pain relief within 10–15 days, with therapeutic effects persisting for several weeks to over 5 years. Many also demonstrated improvements in daily functioning and a reduction in analgesic consumption. No serious adverse events were reported, supporting BoNT-A as a safe and promising treatment for PCH. Conclusion: BoNT-A is a well-tolerated and effective option for patients with refractory PCH, offering substantial pain relief and functional improvement. However, given the reliance on small-scale studies, larger clinical trials are needed to confirm its efficacy and establish standardized treatment protocols.
- 11 June 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-17
Comparison between spinal fusion vs. nonoperative treatment for lumbar degenerative pathology: a systematic review and meta-analysis
Background Lumbar fusion is widely used to treat chronic lumbar degenerative pathology; however, its effectiveness and safety compared with nonoperative management remain controversial. Objectives This systematic review and meta-analysis aimed to evaluate and compare the effectiveness and safety of spinal fusion and conservative management in treating lumbar degenerative pathology. Method A systematic review and meta-analysis were conducted following the PRISMA guidelines. The PubMed, Scopus, Cochrane Central, Web of Science, and Embase databases were searched in October 2024. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting pain reduction and functional disability outcomes. The primary outcomes were changes in the Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) scores for back and leg pain. Data were analyzed using a random-effects model in RevMan 5.4.1, with subgroup and sensitivity analyses performed to address heterogeneity. Results Fourteen studies comprising 13 RCTs and one cohort study, involving 2,399 participants, were included. Spinal fusion showed significant improvements in ODI scores compared to conservative treatment (MD = -6.3; 95% CI [-12.02, -0.57]; p = 0.03), indicating reduced disability. VAS back pain scores also favored spinal fusion (MD = -3.02; 95% CI [-5, 1.04]; p = 0.003), with long-term outcomes showing consistent benefits (MD = -2.26; 95% CI [-3.16, 1.37]; p < 0.00001). However, spinal fusion did not significantly reduce leg pain compared to non-operative options (MD = -2.27; 95% CI [-8.37, 3.83]; p = 0.47). Conclusion Spinal fusion offers statistically significant benefits in reducing disability and back pain compared with conservative treatments for lumbar degenerative pathology. However, it does not confer substantial advantages to leg pain and carries a high surgical risk. These findings emphasize the importance of individualized treatment selection based on patient characteristics and clinical indications.
- 11 June 2025
- Published by Springer Nature in Neurosurgical Review
- Vol. 48 (1) , 1-17
Comparison between spinal fusion vs. nonoperative treatment for lumbar degenerative pathology: a systematic review and meta-analysis
Background Lumbar fusion is widely used to treat chronic lumbar degenerative pathology; however, its effectiveness and safety compared with nonoperative management remain controversial. Objectives This systematic review and meta-analysis aimed to evaluate and compare the effectiveness and safety of spinal fusion and conservative management in treating lumbar degenerative pathology. Method A systematic review and meta-analysis were conducted following the PRISMA guidelines. The PubMed, Scopus, Cochrane Central, Web of Science, and Embase databases were searched in October 2024. Eligible studies included randomized controlled trials (RCTs) and observational studies reporting pain reduction and functional disability outcomes. The primary outcomes were changes in the Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) scores for back and leg pain. Data were analyzed using a random-effects model in RevMan 5.4.1, with subgroup and sensitivity analyses performed to address heterogeneity. Results Fourteen studies comprising 13 RCTs and one cohort study, involving 2,399 participants, were included. Spinal fusion showed significant improvements in ODI scores compared to conservative treatment (MD = -6.3; 95% CI [-12.02, -0.57]; p = 0.03), indicating reduced disability. VAS back pain scores also favored spinal fusion (MD = -3.02; 95% CI [-5, 1.04]; p = 0.003), with long-term outcomes showing consistent benefits (MD = -2.26; 95% CI [-3.16, 1.37]; p < 0.00001). However, spinal fusion did not significantly reduce leg pain compared to non-operative options (MD = -2.27; 95% CI [-8.37, 3.83]; p = 0.47). Conclusion Spinal fusion offers statistically significant benefits in reducing disability and back pain compared with conservative treatments for lumbar degenerative pathology. However, it does not confer substantial advantages to leg pain and carries a high surgical risk. These findings emphasize the importance of individualized treatment selection based on patient characteristics and clinical indications.
- 22 May 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (10) , 4949-4966
Evaluating hyperbaric oxygen therapy as an adjunct to corticosteroids in sudden sensorineural hearing loss: a systematic review and meta-analysis
Background Sudden sensorineural hearing loss (SSNHL) is a medical emergency characterized by unexplained hearing loss, usually one-sided, of at least 30 dB across three or more contiguous frequencies within 72 h. This condition significantly impairs daily communication and has serious consequences for mental health, social relationships, and the overall quality of life. Hyperbaric oxygen therapy (HBOT) is being investigated as a potential adjuvant treatment for SSNHL alongside systemic steroids. Objectives This systematic review and meta-analysis aimed to evaluate the efficacy of HBOT combined with systemic corticosteroids compared with corticosteroids alone in patients with SSNHL. Method We searched PubMed, Cochrane, Scopus, Web of Science, and Google Scholar to identify 14 studies that matched our inclusion criteria of randomized controlled trials (RCTs) published in English, which evaluated HBOT alone or with corticosteroids in adults (≥ 18 years) diagnosed with SSNHL based on the AAO-HNS criteria, reporting pure-tone audiometry (PTA)-based outcomes. The analysis included 794 participants and evaluated outcomes such as improvements in Pure Tone Audiometry (PTA) thresholds, rates of hearing recovery, and adverse events. Results Results indicated that the combined therapy of HBOT and systemic corticosteroids significantly improved low-frequency hearing thresholds (SMD: 0.83, 95% CI: 0.66–1.00, p < 0.0001) and increased the odds of complete recovery (OR: 2.05, 95% CI: 1.41–2.98, p = 0.0002). However, significant heterogeneity (I² = 96.7%) and variations in the treatment protocols were observed. Adverse events, including vertigo, have been reported but are generally mild. Conclusion This meta-analysis suggests that combining systemic corticosteroids with HBOT may improve hearing recovery in ISSNHL, particularly at lower frequencies within the first three months. However, high heterogeneity and the lack of statistical significance in the random-effects model call for cautious interpretation. Well-designed RCTs with standardized protocols and clear patient selection criteria are needed to confirm these findings. Future research should focus on identifying subgroups most likely to benefit and optimizing treatment protocols.
- 22 May 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (10) , 4949-4966
Evaluating hyperbaric oxygen therapy as an adjunct to corticosteroids in sudden sensorineural hearing loss: a systematic review and meta-analysis
Background Sudden sensorineural hearing loss (SSNHL) is a medical emergency characterized by unexplained hearing loss, usually one-sided, of at least 30 dB across three or more contiguous frequencies within 72 h. This condition significantly impairs daily communication and has serious consequences for mental health, social relationships, and the overall quality of life. Hyperbaric oxygen therapy (HBOT) is being investigated as a potential adjuvant treatment for SSNHL alongside systemic steroids. Objectives This systematic review and meta-analysis aimed to evaluate the efficacy of HBOT combined with systemic corticosteroids compared with corticosteroids alone in patients with SSNHL. Method We searched PubMed, Cochrane, Scopus, Web of Science, and Google Scholar to identify 14 studies that matched our inclusion criteria of randomized controlled trials (RCTs) published in English, which evaluated HBOT alone or with corticosteroids in adults (≥ 18 years) diagnosed with SSNHL based on the AAO-HNS criteria, reporting pure-tone audiometry (PTA)-based outcomes. The analysis included 794 participants and evaluated outcomes such as improvements in Pure Tone Audiometry (PTA) thresholds, rates of hearing recovery, and adverse events. Results Results indicated that the combined therapy of HBOT and systemic corticosteroids significantly improved low-frequency hearing thresholds (SMD: 0.83, 95% CI: 0.66–1.00, p < 0.0001) and increased the odds of complete recovery (OR: 2.05, 95% CI: 1.41–2.98, p = 0.0002). However, significant heterogeneity (I² = 96.7%) and variations in the treatment protocols were observed. Adverse events, including vertigo, have been reported but are generally mild. Conclusion This meta-analysis suggests that combining systemic corticosteroids with HBOT may improve hearing recovery in ISSNHL, particularly at lower frequencies within the first three months. However, high heterogeneity and the lack of statistical significance in the random-effects model call for cautious interpretation. Well-designed RCTs with standardized protocols and clear patient selection criteria are needed to confirm these findings. Future research should focus on identifying subgroups most likely to benefit and optimizing treatment protocols.